GlassScriptPhysician profile
David D Picascia
NPI 1306865613
$4,205.46
in general payments reported to CMS, 2019-2025
25 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $26.20 · 2021: $51.61 · 2022: $529 · 2023: $849 · 2024: $1,422 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,340.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.88 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $713.62 | 2022-2025 | |
| Dermavant Sciences, INC. | $571.74 | 2022-2024 | Vtama |
| Pfizer INC. | $528.89 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $252.39 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $169.71 | 2019-2025 | Ilumya |
| Janssen Biotech, INC. | $136.77 | 2022-2024 | Tremfya |
| Incyte Corporation | $122.99 | 2022-2024 | Opzelura |
| Lilly USA, LLC | $118.50 | 2019-2024 | Olumiant, Taltz |
| Leo Pharma INC. | $106.60 | 2019-2025 | Adbry |
| Galderma Laboratories, L.P. | $99.77 | 2024-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $91.87 | 2019-2025 | Dupixent |
| Organon LLC | $87.65 | 2025 | Vtama |
| Genzyme Corporation | $87.46 | 2020-2025 | |
| Amgen INC. | $82.26 | 2024 | Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $53.13 | 2022-2023 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.36 | 2019 | |
| Biofrontera INC. | $40.15 | 2021-2022 | |
| Aclaris Therapeutics, INC. | $17.11 | 2019 | |
| Mission Pharmacal Company | $15.59 | 2019 | |
| Krystal Biotech INC | $15.19 | 2025 | Vyjuvek |
| Sebela Pharmaceuticals INC. | $14.03 | 2019 | |
| Lnhc, INC | $13.88 | 2025 | Zelsuvmi |
| Prugen, INC. Pharmaceuticals | $13.77 | 2019 | |
| Ucb, INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Picascia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.